Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2022 | The latest updates on tafasitamab in DLBCL

Jason Westin • 4 Oct 2022
SOHO 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide R-CHOP Tafasitamab

Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the latest updates on the use of tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL) and ongoing clinical trials evaluating this agent. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding from Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, and ADC Therapeutics, and consulting with Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, ADC Therapeutics, Merck, and MonteRosa.

More from Jason Westin

An update on T-cell engagers in follicular lymphoma and large B-cell lymphoma
9:46
An update on T-cell engagers in follicular lymphoma and large B-cell lymphoma
Jason Westin et al. • 25 Apr 2026
GOLSEEK-1 trial: golcadomide plus R-CHOP in frontline high-risk large B-cell lymphoma
1:02
GOLSEEK-1 trial: golcadomide plus R-CHOP in frontline high-risk large B-cell lymphoma
Jason Westin • 7 Dec 2025
ALPHA3 study: first-line consolidation with cema-cel in MRD-positive LBCL after standard therapy
0:55
ALPHA3 study: first-line consolidation with cema-cel in MRD-positive LBCL after standard therapy
Jason Westin • 7 Dec 2025
Rapcabtagene autoleucel for patients with first-line high-risk LBCL: Phase II interim results
1:05
Rapcabtagene autoleucel for patients with first-line high-risk LBCL: Phase II interim results
Jason Westin • 7 Dec 2025

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals